Proposed removal of risk statements about cardiovascular diseases, breast cancer, and probable dementia from the boxed warnings, as well as other proposed safety-related labeling changes, to clarify the benefit/risk considerations for these drugs.
Similar Posts
Dr. Reddy’s Laboratories, LTD, Biologics – 09/12/2025
Dr. Reddy’s Laboratories, LTD, Biologics – 09/12/2025. Country: India. Record Type: 483Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee) Roster
This page contains the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee) Roster, which lists the current members and the current number of vacancies for the committee.Biosimilars Research: Awards
Biosimilars Research: AwardsDevelopment of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ Effects
Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ EffectsStudy of Sex Differences in the Clinical Evaluation of Medical Products
This guidance provides recommendations for increasing enrollment of females in clinical trials, analyzing and interpreting sex-specific data, and including sex-specific information in regulatory submissions of medical productsFollow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices – Letter to Health Care Providers
The FDA is reminding the public about the safe use of hyperbaric oxygen therapy devices and is providing recommendations to help reduce potential risks.